TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06883539: A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.

Sponsor: LaunXP Biomedical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,015,936

Rescue Site Savings

+$1,979,208

Unlock Full NCT06883539 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06883539 Rescue Dossier →